Dietmar Siemann

Department of Radiation Oncology, University of Florida

Research Area

Biography

Dietmar Siemann has not added Biography.
If you are Dietmar Siemann and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 4	2021

Other Publications

Article	Year
Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. International journal of cancer\| PubMed ID: 11948484	2002
Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta oncologica (Stockholm, Sweden)\| PubMed ID: 11990525	2002
Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. International journal of radiation oncology, biology, physics\| PubMed ID: 12007956	2002
Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer gene therapy\| PubMed ID: 12032662	2002
Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. International journal of radiation oncology, biology, physics\| PubMed ID: 12459379	2002
Enhancement of radiation therapy by vascular targeting agents. Current opinion in investigational drugs (London, England : 2000)\| PubMed ID: 12476970	2002
Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Seminars in radiation oncology\| PubMed ID: 12520464	2003
Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus. Anticancer research\| PubMed ID: 12530082	2002
Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology\| PubMed ID: 12559515	2003
Postoperative radiation therapy for squamous cell carcinoma of the head and neck. American journal of otolaryngology\| PubMed ID: 12579482	2003
Simultaneous targeting of VEGF message and VEGF receptor signaling as a therapeutic anticancer approach. Anticancer research\| PubMed ID: 15015599	2004
Targeting the tumor vasculature: a strategy to improve radiation therapy. Expert review of anticancer therapy\| PubMed ID: 15056061	2004
Vascular-targeting therapies for treatment of malignant disease. Cancer\| PubMed ID: 15197790	2004
Therapeutic strategies that selectively target and disrupt established tumor vasculature. Hematology/oncology clinics of North America\| PubMed ID: 15474333	2004
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. International journal of radiation oncology, biology, physics\| PubMed ID: 15519796	2004
Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology\| PubMed ID: 15588883	2004
Differentiation and definition of vascular-targeted therapies. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 15701823	2005
The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. International journal of radiation oncology, biology, physics\| PubMed ID: 15936569	2005
Radiotherapy alone or combined with carbogen breathing for squamous cell carcinoma of the head and neck: a prospective, randomized trial. Cancer\| PubMed ID: 15937906	2005
Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In vivo (Athens, Greece)\| PubMed ID: 16277020	2005
Preclinical studies of the novel vascular disrupting agent MN-029. Anticancer research\| PubMed ID: 16309177	2005
Recombinant adeno-associated and adenoviral vectors for the transduction of pancreatic and colon carcinoma. Anticancer research\| PubMed ID: 16475712	2006
VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy. International journal of radiation oncology, biology, physics\| PubMed ID: 16751064	2006
Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 16818709	2006
Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique. European journal of cancer (Oxford, England : 1990)\| PubMed ID: 16956760	2006
Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. Anticancer research\| PubMed ID: 17094465	2006
Impact of VEGF expression on the physiological characteristics of clonal cell lines. In vivo (Athens, Greece)\| PubMed ID: 17203773	2006
Characterizing the tumor response to treatment with combretastatin A4 phosphate. International journal of radiation oncology, biology, physics\| PubMed ID: 17448875	2007
Monitoring the treatment efficacy of the vascular disrupting agent CA4P. European journal of cancer (Oxford, England : 1990)\| PubMed ID: 17451938	2007
Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 18566400	2008
Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer research\| PubMed ID: 18751370	2008
Vascular targeted therapies in oncology. Cell and tissue research\| PubMed ID: 18752004	2009
Intrinsic radiosensitivity and repair of sublethal radiation-induced damage in canine osteosarcoma cell lines. American journal of veterinary research\| PubMed ID: 18764694	2008
Development of an intramuscular xenograft model of canine osteosarcoma in mice for evaluation of the effects of radiation therapy. American journal of veterinary research\| PubMed ID: 19119958	2009
The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts. International journal of radiation oncology, biology, physics\| PubMed ID: 19215823	2009
A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert opinion on investigational drugs\| PubMed ID: 19236265	2009
X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas. Translational oncology\| PubMed ID: 19252749	2009
Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474). Anticancer research\| PubMed ID: 19528456	2009
Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger. Blood\| PubMed ID: 19717647	2009
In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503. Oncology reports\| PubMed ID: 20127007	2010
Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. The Journal of urology\| PubMed ID: 20303530	2010
Leukemia regression by vascular disruption and antiangiogenic therapy. Blood\| PubMed ID: 20472832	2010
BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Molecular cancer therapeutics\| PubMed ID: 20515943	2010
The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer treatment reviews\| PubMed ID: 20570444	2011
Temporal aspects of the action of ASA404 (vadimezan; DMXAA). Expert opinion on investigational drugs\| PubMed ID: 20964495	2010
Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503. Microvascular research\| PubMed ID: 20974154	2011
Impact of hypoxia on the metastatic potential of human prostate cancer cells. International journal of radiation oncology, biology, physics\| PubMed ID: 21640519	2011
Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells. Gene therapy\| PubMed ID: 21776025	2012
Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. International journal of radiation biology\| PubMed ID: 21815749	2011
Restraint of angiogenesis by zinc finger transcription factor CTCF-dependent chromatin insulation. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 21896759	2011
E-cadherin plasticity in prostate cancer stem cell invasion. American journal of cancer research\| PubMed ID: 21968440	2011
Another road leads to HIF-1 activation: implications for prostate cancer progression. Asian journal of andrology\| PubMed ID: 22101943	2012
Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells. Clinical & experimental metastasis\| PubMed ID: 22130962	2012
Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation. Clinical & experimental metastasis\| PubMed ID: 22286523	2012
Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617. Microvascular research\| PubMed ID: 22387475	2012
Src-signaling interference impairs the dissemination of blood-borne tumor cells. Cell and tissue research\| PubMed ID: 22526632	2012
Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. BMC cancer\| PubMed ID: 22639908	2012
Vascular development in mouse lung metastases. American journal of cancer research\| PubMed ID: 22957309	2012
Cell-based selection provides novel molecular probes for cancer stem cells. International journal of cancer\| PubMed ID: 23150432	2013
Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo. Blood\| PubMed ID: 23212515	2013
An update on the clinical development of drugs to disable tumor vasculature. Expert opinion on drug discovery\| PubMed ID: 23484531	2007
Adenomatous polyposis coli-mediated accumulation of abasic DNA lesions lead to cigarette smoke condensate-induced neoplastic transformation of normal breast epithelial cells. Neoplasia (New York, N.Y.)\| PubMed ID: 23555190	2013
Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice. American journal of veterinary research\| PubMed ID: 23627391	2013
Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells. Clinical & experimental metastasis\| PubMed ID: 23748470	2013
Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model. Journal of applied physiology (Bethesda, Md. : 1985)\| PubMed ID: 24177690	2013
Effects of aurothiomalate treatment on canine osteosarcoma in a murine xenograft model. Anti-cancer drugs\| PubMed ID: 24304691	2014
MRI-based computational model of heterogeneous tracer transport following local infusion into a mouse hind limb tumor. PloS one\| PubMed ID: 24619021	2014
Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise. Journal of the National Cancer Institute\| PubMed ID: 24627275	2014
In vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors. Biomedical optics express\| PubMed ID: 24940553	2014
Limitations of the dorsal skinfold window chamber model in evaluating anti-angiogenic therapy during early phase of angiogenesis. Vascular cell\| PubMed ID: 25101168	2014
Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference. Cancer letters\| PubMed ID: 25312939	2016
Histone Methyltransferase hSETD1A Is a Novel Regulator of Metastasis in Breast Cancer. Molecular cancer research : MCR\| PubMed ID: 25373480	2015
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner. Cancer letters\| PubMed ID: 25676691	2015
Modulation of the tumor vasculature and oxygenation to improve therapy. Pharmacology & therapeutics\| PubMed ID: 26073310	2015
Cathepsin L targeting in cancer treatment. Pharmacology & therapeutics\| PubMed ID: 26299995	2015
Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L. Bioorganic & medicinal chemistry\| PubMed ID: 26462052	2015
Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model. International journal of cancer\| PubMed ID: 26757413	2016
Chemosensitizing AML cells by targeting bone marrow endothelial cells. Experimental hematology\| PubMed ID: 26898708	2016
Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94. Clinical & experimental metastasis\| PubMed ID: 27055649	2016
Hypoxia regulates SOX2 expression to promote prostate cancer cell invasion and sphere formation. American journal of cancer research\| PubMed ID: 27294000	2016
Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells. The Journal of clinical investigation\| PubMed ID: 27721239	2016
Exercise and the Tumor Microenvironment: Potential Therapeutic Implications. Exercise and sport sciences reviews\| PubMed ID: 29166299	2018
Have Clinical Trials Properly Assessed c-Met Inhibitors? Trends in cancer\| PubMed ID: 29458966	2018
Tumor oxygenation and cancer therapy-then and now. The British journal of radiology\| PubMed ID: 29513032	2019
Treatment with Src inhibitor Dasatinib results in elevated metastatic potential in the 4T1 murine mammary carcinoma model. Tumor & microenvironment\| PubMed ID: 29658958	2018
Stromal cells in breast cancer as a potential therapeutic target. Oncotarget\| PubMed ID: 29805773	2018
Stability and Mobility of Magnetic Nanoparticles in Biological Environments Determined from Dynamic Magnetic Susceptibility Measurements. Bioconjugate chemistry\| PubMed ID: 30011185	2018
Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion. Oncotarget\| PubMed ID: 30719213	2019
Reliability of blood lactate as a measure of exercise intensity in different strains of mice during forced treadmill running. PloS one\| PubMed ID: 31050686	2019
Axl signaling is an important mediator of tumor angiogenesis. Oncotarget\| PubMed ID: 31080559	2019
Prostate cancer cell growth characteristics in serum and prostate-conditioned media from moderate-intensity exercise-trained healthy and tumor-bearing rats. American journal of cancer research\| PubMed ID: 31105994	2019
c-Src is required for hypoxia-induced metastasis-associated functions in prostate cancer cells. OncoTargets and therapy\| PubMed ID: 31190858	2019
Cathepsin L secretion by host and neoplastic cells potentiates invasion. Oncotarget\| PubMed ID: 31565189	2019
Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment. Cancers\| PubMed ID: 32660000	2020
Bioprinting on Live Tissue for Investigating Cancer Cell Dynamics. Tissue engineering. Part A\| PubMed ID: 33059528	2021
Inhibition of the Axl pathway impairs breast and prostate cancer metastasis to the bones and bone remodeling. Clinical & experimental metastasis\| PubMed ID: 33791875	2021
Using a combination of gangliosides and cell surface vimentin as surface biomarkers for isolating osteosarcoma cells in microfluidic devices. Journal of bone oncology\| PubMed ID: 33912384	2021
Normal tissue and tumor microenvironment adaptations to aerobic exercise enhance doxorubicin anti-tumor efficacy and ameliorate its cardiotoxicity in retired breeder mice. Oncotarget\| PubMed ID: 34504647	2021
Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer. International journal of molecular sciences\| PubMed ID: 34576116	2021